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Abstract
Background: During scleroderma (SSc) pathogenesis, fibroblasts acquire an activated phenotype characterized by
enhanced production of extracellular matrix (ECM) and constitutive activation of several major signaling pathways
including extracellular signal-related kinase (ERK1/2). Several studies have addressed the role of ERK1/2 in SSc
fibrosis however the mechanism of its prolonged activation in SSc fibroblasts is still unknown. Protein phosphatase
2A (PP2A) is a key serine threonine phosphatase responsible for dephosphorylation of a wide array of signaling
molecules. Recently published microarray data from cultured SSc fibroblasts suggests that the catalytic subunit
(C-subunit) of PP2A is downregulated in SSc. In this study we examined the role and regulation of PP2A in SSc
fibroblasts in the context of ERK1/2 phosphorylation and matrix production.
Results: We show for the first time that PP2A mRNA and protein expression are significantly reduced in SSc
fibroblasts and correlate with an increase in ERK1/2 phosphorylation and collagen expression. Furthermore,
transforming growth factor b (TGFb), a major profibrotic cytokine implicated in SSc fibrosis, downregulates PP2A
expression in healthy fibroblasts. PP2A-specific small interfering RNA (siRNA) was utilized to confirm the role of
PP2A in ERK1/2 dephosphorylation in dermal fibroblasts. Accordingly, blockade of autocrine TGFb signaling in SSc
fibroblasts using soluble recombinant TGFb receptor II (SRII) restored PP2A levels and decreased ERK1/2
phosphorylation and collagen expression. In addition, we observed that inhibition of ERK1/2 in SSc fibroblasts
increased PP2A expression suggesting that ERK1/2 phosphorylation also contributes to maintaining low levels of
PP2A, leading to an even further amplification of ERK1/2 phosphorylation.
Conclusions: Taken together, these studies suggest that decreased PP2A levels in SSc is a result of constitutively
activated autocrine TGFb signaling and could contribute to enhanced phosphorylation of ERK1/2 and matrix
production in SSc fibroblasts.
Introduction
Scleroderma (SSc) is an autoimmune connective tissue
disease characterized by excess production and deposi-
tion of extracellular matrix proteins leading to fibrosis
of the tissue. During this process, normal fibroblasts
become ‘activated’ and acquire a fibrotic phenotype.
Transforming growth factor b (TGFb)i sam a j o rp r o f i -
brotic cytokine that plays important roles in a variety of
physiological processes including cell proliferation, dif-
ferentiation and survival. Although the mechanism of
SSc fibrosis is not fully understood, there is strong evi-
dence to suggest that TGFb is central to the develop-
ment and maintenance of the SSc phenotype [1-3].
Normal healthy dermal fibroblasts treated with TGFb
reproduce characteristics of SSc fibroblasts, further
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SSc fibrosis [4].
During tissue injury, rapid release of TGFb attracts
inflammatory cells and fibroblasts to the site of injury,
resulting in extracellular matrix production/remodeling
and myofibroblast differentiation [5]. In normal tissue,
following the injury response, coordinated apoptosis of
fibroblasts and myofibroblasts prevents scarring and
excessive fibrosis [6]. Published data suggests that nor-
mal and SSc dermal fibroblasts in culture secrete simi-
lar levels of TGFb ligand [7,8] However, there is
evidence of increased TGFb signaling in SSc fibroblasts
when compared to normal fibroblasts. Several studies
have shown elevated levels of TGFb receptors in SSc
fibroblasts, which contribute to an autocrine TGFb sig-
naling cascade that is maintained in culture even in the
absence of exogenous ligand [9-11]. The chronic acti-
vation of the TGFb pathway in SSc produces fibro-
blasts with constitutively activated Akt and ERK1/2
pathways that are resistant to apoptosis [12-14]. The
ERK1/2 pathway regulates numerous cellular processes
and more recently has also been implicated in the pro-
cess of fibrosis. Several papers have reported the func-
tion of the activated ERK1/2 pathway in fibrosis. For
example, it has been demonstrated that the ERK1/2
pathway is required for Smad1 phosphorylation in
response to overexpression of TGFbRI and for subse-
quent upregulation of connective tissue growth factor
(CCN2) and other profibrotic genes [15]. Activation of
mitogen-activated protein kinase kinase 1(MEK1)/
E R K 1 / 2p a t h w a yw a sa l s os h o w nt ob eap r i m a r y
mechanism responsible for the TGFb-induced upregu-
lation of early growth response factor 1 (Egr-1) [16]. In
addition, Chen et al. recently reported that activation
of the ERK1/2 pathway contributes to the enhanced
fibrosis and contractile ability of scleroderma fibro-
blasts [12]. The ERK1/2 pathway also induces up regu-
lation of avb3 integrin, which contributes to the
autocrine TGFb signaling in scleroderma fibroblasts
[ 1 7 ] .H o w e v e r ,a l t h o u g hc o n s t itutively phosphorylated
ERK1/2 may play important roles in SSc pathogenesis,
the mechanism of prolonged activation of this pathway
is largely unknown.
Protein phosphatase 2A (PP2A) is a member of the
PPP family and one of the most abundant serine-threo-
nine phosphatases, accounting for a substantial part of
the total phosphatase activity. PP2A plays an important
role in signal transduction pathways, regulation of cell
cycle and transcriptional and translational regulation
[18]. PP2A has a complex structure, comprising of three
subunits: the catalytic (C), regulatory (B) and structural
subunit (A). The catalytic subunit (C) and structural
subunit (A) have two isoforms: a and b.T h er e g u l a t o r y
subunit (B) consists of four families with many isoforms
that confer specificity of location and function [18]. The
phosphatase activity of PP2A is present in the C-subunit
and its effects include dephosphorylation of various
transcription factors and protein kinases including
MEK, ERK1/2, Akt, and sphingosine kinase (SK)
[19-21]. Recently published microarray data from cul-
tured early passage SSc fibroblasts suggests that the b
isoform of the catalytic subunit of PP2A is downregu-
lated in SSc [22]. Based on the evidence of constitutive
activation of ERK1/2 pathways in SSc fibroblasts and
recent microarray data suggesting that PP2A may also
be altered in SSc, we wished to further study the
mechanism and significance of dysregulated PP2A in
SSc fibroblasts.
Results
TGFb stimulates prolonged phosphorylation of ERK1/2 in
dermal fibroblasts
Because of the central role of TGFb in the pathogenesis
of SSc, we first examined the regulation of ERK1/2
phosphorylation by TGFb treatment in healthy fibro-
blasts. To investigate the kinetics of ERK1/2 activation,
time course experiments were performed. Near conflu-
ent cells were serum starved and then treated with
TGFb for increasing time periods ranging from 0-24 h.
Using western blot analysis we observed that stimulation
of cells with TGFb resulted in rapid phosphorylation of
ERK1/2 as early as 15 min and sustained ERK1/2 phos-
phorylation up to 24 h (Figure 1a). This suggests that
TGFb can activate both early and prolonged phosphory-
lation of ERK1/2 in dermal fibroblasts.
PP2A expression is decreased upon treatment with TGFb
Since PP2A has been previously described as a major
ERK1/2 phosphatase we next sought to determine
whether TGFb c o u l da l s ob ei n v o l v e di nt h er e g u l a t i o n
of PP2A expression in dermal fibroblasts. Confluent der-
mal fibroblasts were serum starved and then treated
with TGFb for different time periods. The mRNA levels
of a and b isoforms of the PP2A catalytic subunit were
analyzed by quantitative reverse transcription (qRT)-
PCR. As shown in Figure 1b, the mRNA levels of PP2A
were decreased as early as 6 h after TGFb addition and
the lower levels persisted up to 48 h. Treatment of cells
with TGFb affected both catalytic subunit isoforms, but
the b isoform showed a greater overall decrease. To
further validate the effects of TGFb on PP2A gene
expression we measured the protein levels of PP2A (Fig-
ure 1c,d) after 24 h of TGFb treatment. PP2A protein
levels were decreased at 24 h, correlating with and con-
firming the mRNA data. These observations show that
TGFb negatively regulates PP2A expression, suggesting
that PP2A may be involved in TGFb-mediated ERK1/2
phosphorylation.
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phosphorylation
To further confirm the role of PP2A in ERK1/2 phos-
phorylation in dermal fibroblasts, experiments were per-
formed using okadaic acid (OA), a pharmacological
inhibitor of PP2A activity, and PP2A-specific small
interfering RNA (siRNA). Upon treatment of normal
dermal fibroblasts with OA (2 nM) for 1 h, increased
ERK1/2 phosphorylation was observed (Figure 2a). Con-
sistent with this data, siRNA against the catalytic subu-
nit of PP2A also increased phosphorylation levels of
ERK1/2, suggesting that PP2A is involved in ERK1/2
dephosphorylation (Figure 2b,c). From these experi-
ments we can conclude that PP2A downregulation in
S S cf i b r o b l a s t sm a yc o n t r i b u t et oe n h a n c e dE R K 1 / 2
phosphorylation. This data is in accordance with pre-
viously published reports that PP2A is an ERK1/2 phos-
phatase in several different cell types.
PP2A expression is decreased and correlates with
increased ERK1/2 phosphorylation in SSc dermal
fibroblasts
To further study the relationship of PP2A and ERK1/2
phosphorylation in the pathological context, age, race
and gender matched SSc and normal dermal fibroblasts
obtained from patient biopsy were analyzed for PP2A
expression and ERK1/2 activation. ERK1/2 phosphoryla-
tion was increased in SSc fibroblasts, consistent with
data from previous reports [12] (Figure 3a). The mRNA
levels of both isoforms of the PP2A C-subunit were
significantly decreased in SSc fibroblasts when compared
to normal controls (Figure 3b). Consistent with the
mRNA data, the protein levels of the catalytic subunit of
PP2A were significantly lower in SSc fibroblasts com-
pared to normal controls (Figure 3c). The observations
from SSc fibroblasts are consistent with the results from
normal fibroblasts treated with TGFb that show PP2A
downregulation, suggesting a role for TGFb in mediat-
ing these changes in SSc fibroblasts.
Autocrine TGFb signaling regulates PP2A expression in
SSc fibroblasts
Autocrine TGFb signaling has been reported to play a
major role in the pathogenesis of SSc. and blockade of
endogenous TGFb signaling has been shown to attenu-
ate the scleroderma fibrotic phenotype [8]. Recombinant
soluble TGFb receptor II (SRII) has been successfully
used as a TGFb antagonist to block the effects of TGFb
signaling such as upregulated collagen production. SRII
binds TGFb ligand and prevents its interaction with sur-
face receptors thereby neutralizing its activity [23,24].
To further investigate whether TGFb signaling is
responsible for the decreased levels of PP2A in SSc, we
blocked autocrine TGFb signaling using SRII. As a con-
trol experiment to confirm the effectiveness of SRII,
normal cells were pretreated with SRII for 1 h and then
treated with TGFb for 24 h. Pretreatment with SRII effi-
ciently blocked downregulation of PP2A by TGFb
Figure 1 Transforming growth factor (TGF)b regulates extracellular signal-regulated kinase (ERK)1/2 phosphorylation and protein
phosphatase 2A (PP2A) expression in dermal fibroblasts. (a) Adult dermal fibroblasts were treated with TGFb (5 ng/ml) for 0 h, 15 min, 1 h,
3 h, 6 h, 12 h and 24 h after serum starvation. Western blot analysis was performed using phospho-ERK1/2 and ERK1/2 primary antibodies and
rabbit horseradish peroxidase-conjugated secondary antibody. (b) Adult dermal fibroblasts were serum starved overnight and treated with 5 ng/
ml of TGFb for 0 h, 6 h, 12 h, 24 h and 48 h. RNA was then extracted and cDNA synthesized for quantitative PCR analysis; n = 3, *P < 0.05, **P <
0.01. (c) Dermal fibroblasts were treated for 24 h with 5 ng/ml of TGFb after 24 h of serum starvation, and western blot analysis was performed
using a PP2A antibody directed against the catalytic subunit; n = 5, representative blot of three experiments. (d) Bar graphs represent
quantification of western blot analysis from (c); n = 5, *P < 0.05 versus normal control.
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expression in scleroderma (SSc) fibroblasts. Dermal fibroblasts obtained from SSc patients and matched controls were grown to confluence
and then serum starved for 24 h. Cells were collected and in (a) the levels of ERK1/2 phosphorylation were analyzed by western blot. In (b), the
mRNA levels of the PP2A catalytic subunits a and b were analyzed using quantitative PCR. The mRNA values were normalized relative to
matched controls (arbitrarily set as 1) and means ± standard error of the mean (SEM) of five independent experiments are shown (*P < 0.01). (c)
The total protein levels of the PP2A catalytic subunit were measured by western blot. b Actin was used as a loading control.
Figure 2 Protein phosphatase 2A (PP2A) blockade stimulates extracellular signal-regulated kinase (ERK)1/2 phosphorylation in dermal
fibroblasts. (a) Dermal fibroblasts were treated with 2 nm of okadaic acid (OA) for 1 h and protein levels of phosphorylated ERK1/2 were
measured by western blot. (b) Normal dermal fibroblasts were treated with 100 nm PP2A siRNA or scramble control for 48 h. Cell extracts were
then analyzed for phosphorylated ERK1/2 after PP2A blockade. (c) Bar graph shows quantification of phospho-ERK1/2 after treatment with PP2A
siRNA; P < 0.05. b Actin was used as the loading control.
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showed no significant difference in basal PP2A expres-
sion (Figure 4b). We next determined the effects of SRII
treatment on PP2A levels in SSc fibroblasts. Dermal
fibroblasts obtained from three different SSc patient
biopsies were grown to confluence, serum starved over-
night and then treated with SRII for 24 h. The protein
levels of PP2A were increased in SSc fibroblasts in the
presence of SRII, suggesting that PP2A gene expression
is regulated by the autocrine TGFb signaling in these
cells (Figure 4c). Increased expression of PP2A after
SRII treatment was accompanied by a decrease in
ERK1/2 phosphorylation and collagen expression (Figure
4c) providing evidence for a possible role for PP2A in
the enhanced ERK1/2 phosphorylation and collagen
expression observed in SSc.
Blockade of ERK1/2 phosphorylation increases PP2A
expression in SSc fibroblasts
The activity of kinases and phosphatases is tightly regu-
lated in the cell and often involve feedback mechanisms,
which help maintain the levels of cellular phosphoryla-
tion. A study performed in human lung fibroblasts
suggests that silencing of ERK1/2 is associated with a
decrease in PP2A activity [25]. In order to further
explore the relationship between PP2A and ERK1/2
phosphorylation, we examined the possibility that ERK1/
2 activation could play a role in regulating the PP2A
levels in SSc fibroblasts. SSc and normal dermal fibro-
blasts were treated with the pharmacological inhibitor
U0126 to block ERK1/2 phosphorylation. Interestingly,
only SSc fibroblasts showed increased PP2A expression
upon treatment with U0126, suggesting that ERK1/2
activation contributes to maintaining decreased PP2A
levels in SSc (Figure 5a,b). No significant change in
PP2A levels in normal fibroblasts was observed (Data
not shown). Taken together, these results suggest that
autocrine TGFb signaling in SSc fibroblasts leads to
activation of ERK1/2 which in turn downregulates PP2A
levels, thereby leading to even more prolonged phos-
phorylation of ERK1/2.
PP2A is a negative regulator of collagen expression
Fibrosis is the hallmark of SSc fibroblasts and dysregula-
tion of various signaling pathways have been implicated
in increased collagen production in this disease. In SSc
Figure 4 Autocrine transforming growth factor (TGF)b signaling regulates protein phosphatase 2A (PP2A) expression in scleroderma
(SSc) fibroblasts. (a) Normal dermal fibroblasts were pretreated with recombinant transforming growth factor b soluble receptor II (SRII) (10 ng/
ml) for 1 h and then treated with 5 ng/ml of TGFb for 24 h. Western blot analysis was used to determine PP2A levels. (b) Normal and (c) SSc
dermal fibroblasts were treated with SRII for 24 h after serum deprivation. Cells were collected and total protein levels of PP2A catalytic subunit
were analyzed by western blot. In SSc cells, cell lysates were also analyzed for phospho-extracellular signal-regulated kinase (ERK)1/2 and type 1
collagen. b Actin was used as a loading control. (d) Bar graph shows quantification of PP2A protein expression after treatment of SSc fibroblasts
with SRII; *P < 0.05.
Samuel et al. Fibrogenesis & Tissue Repair 2010, 3:25
http://www.fibrogenesis.com/content/3/1/25
Page 5 of 9fibroblasts we observed an inverse correlation between
PP2A levels and collagen expression (Figure 6a). To
further determine whether PP2A blockade may contri-
bute to increased collagen, normal dermal fibroblasts
were treated with a specific pharmacological inhibitor of
P P 2 A ,O A( 2n m )f o r2 4h .T h i sl o wd o s eo fO A( 2
nM) stimulated a modest increase in collagen protein
levels (Figure 6b). However at higher doses we did not
see this effect (data not shown). To further confirm the
role of PP2A in regulation of collagen, we used siRNA
specific for the catalytic subunit of PP2A. After PP2A
blockade, in most cell lines tested we observed modest
increases in mRNA and protein levels of collagen
(Figure 6c,d).
Discussion
I nt h i ss t u d yw eh a v ed e m o n s t r a t e dt h a tT G F b is a
negative regulator of PP2A. We found decreased expres-
sion of both the a and b isoform of the catalytic subunit
of PP2A after TGFb stimulation. To our knowledge this
is the first report to demonstrate that TGFb is a nega-
tive regulator of PP2A gene expression. In accordance
with previously published studies our data also confirms
that TGFb treatment activates prolonged ERK1/2 phos-
phorylation. This study provides new evidence for the
contribution of PP2A to the pathogenesis of SSc. Analy-
sis of fibroblasts cultured from SSc skin biopsies shows
decreased protein levels of the PP2A catalytic subunit,
with downregulation of both a and b isoforms at the
Figure 6 Protein phosphatase 2A (PP2A) is a negative regulator of collagen expression. (a) Extracts from normal and scleroderma (SSc)
dermal fibroblasts were tested for PP2A and collagen expression using western blot analysis. b Actin was used as the loading control; n = 3,
representative blot shown. (b) After treatment with okadaic acid (OA; 2 nM) collagen expression was determine using western blot analysis in
SSc fibroblasts; n = 3, representative blot shown. (c,d) Normal dermal fibroblasts were treated with PP2A siRNA (100 nM) and collagen mRNA
and protein expression measured. b Actin was used as the loading control; n = 3, representative blot shown.
Figure 5 Extracellular signal-regulated kinase (ERK)1/2 phosphorylation is a negative regulator of protein phosphatase 2A (PP2A)
expression in scleroderma (SSc) fibroblasts. (a) After treatment with ERK1/2 inhibitor U0126 (10 nm) for 24 h, PP2A expression was
determined using western blot analysis in SSc fibroblasts; P < 0.05. (b) Bar graph showing quantification of PP2A expression from (a).
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mal dermal fibroblasts. These data validate a previous
gene array study, which showed decreased levels of the
b isoform in cultured SSc fibroblasts. However, downre-
gulation of the a isoform, which is the most abundant
isoform in vivo, has not been described in SSc fibro-
blasts. Previous reports indicated that an autocrine
TGFb signaling pathway contributes to the SSc pheno-
type [4]. We hypothesized that PP2A downregulation in
SSc could be the result of constitutive TGFb signaling.
This hypothesis was supported by our data showing that
recombinant soluble TGFb receptor II, an antagonist of
TGFb signaling, was able to block the downregulation
of PP2A and to reverse the constitutive phosphorylation
of ERK1/2 in cultured SSc fibroblasts. This suggests that
autocrine TGFb signaling in SSc induces prolonged
ERK1/2 phosphorylation, possibly via modulation of
PP2A expression. Furthermore, in our study we
observed that activated ERK1/2 can suppress PP2A
expression in SSc fibroblasts but not in normal control
fibroblasts. This suggested the presence of a self-sus-
tained signaling loop between PP2A and ERK1/2 in SSc
fibroblasts, whereby increased ERK1/2 phosphorylation
in response to TGFb downregulates PP2A expression
and in turn results in a further increase in ERK1/2
phosphorylation. ERK1/2 phosphorylation has been pre-
viously implicated in fibrosis [12,26,27]. In this study,
we observe that PP2A is also involved in regulation of
collagen. The modest increase in collagen upon PP2A
blockade suggests that the collagen production in SSc
fibroblasts is a cumulative result of many dysregulated
pathways present in SSc fibroblasts.
Reversible protein phosphorylation plays a central role
in the regulation of vast majority of the biological pro-
cesses. This process is tightly controlled by the protein
kinases and phosphatases that together regulate the levels
of cellular phosphoproteins. The balance between the
activities of kinases and phosphatases is often disrupted
during pathological conditions including neurodegenera-
tive diseases and cancer [18,28]. Persistent downregulation
of PP2A in SSc fibroblasts strongly suggests that this path-
way is involved is the pathogenesis of SSc. It is noteworthy
that the study of Tan and colleagues [22], who first
reported on the aberrant expression of PP2A, was per-
formed using fibroblasts from uninvolved skin. This sug-
gests that this defect is present in the early stages of the
disease. The constitutive activation of the ERK1/2 pathway
in SSc may play a critical role in the development and
maintenance of fibrosis and the activated status of
explanted SSc fibroblasts. In addition to its role as a major
ERK1/2 phosphatase, PP2A has been also implicated in
the regulation of sphingosine kinase (SK), a profibrogenic
sphingolipid enzyme induced by TGFb [20,29]. SK cata-
lyzes the conversion of sphingosine to sphingosine1
phosphate, which mimics some of the profibrotic effects of
TGFb [30,31]. Additionally, SK is a major prosurvival
molecule and may also indirectly contribute to fibrosis by
inducing resistance to apoptosis in activated fibroblasts
[31]. Further experiments using animal models of PP2A
knockout or transgenic mice would be essential to study
and dissect the pathways involved in PP2A downregula-
tion in vivo and its role in fibrosis. However there are sev-
eral limitations to this approach considering the vast
number of subunits and splice variants present for this
molecule as well as the numerous substrates and methods
of posttranslational regulation. Several experimental
mouse models have been generated including the PP2AC
knockout mouse and transgenic models of various other
PP2A subunits [32]. The PP2Aca knockout mouse is
embryonic lethal and results in degeneration of the
embryo and lack of formation of the mesoderm. Interest-
ingly, in these embryos, the two highly homologous cataly-
tic subunits are found in different subcellular locations,
the Ca in the plasma membrane and Cb in the cytosol,
making it unlikely that Cb can compensate for Ca in these
mice [32]. However, since these mice are embryonic lethal,
a tissue-specific knockout of PP2Aca in fibroblasts would
provide key insights into the role of PP2A in fibrosis.
Conclusions
In conclusion, this study describes a novel role for
TGFb in the regulation of PP2A gene expression. While
our study focused on ERK1/2, PP2A dephosphorylates
numerous signaling molecules, many of them with a
potential role in fibrosis, and it is likely that such global
downregulation of PP2A activity would modulate addi-
tional cellular pathways. We also show that SSc fibro-
blasts have decreased levels of PP2A and that this could
be restored by blockade of autocrine TGFb signaling,
suggesting that negative regulation of the PP2A catalytic
subunit gene expression may be a physiological mechan-
ism by which sustained ERK1/2 phosphorylation occurs
in SSc. This study highlights an unanticipated regulatory
function for TGFb in modulating PP2A activity and pro-
vides support for an essential role of PP2A in the patho-
genesis of SSc. Further studies are necessary to gain
insight into the role of PP2A and ERK1/2 activation in
the modulation of ECM components in SSc fibroblasts.
Methods
Reagents
The following antibodies were used: anti-PP2A (Upstate,
Temecula, CA, USA), anti-phospho-ERK1/2, anti-ERK1/
2, anti-Akt (Cell Signaling, Beverly, MA, USA), anti-
phospho-Akt, Ser 473 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), monoclonal b actin (Sigma Aldrich, St
Louis, MO, USA), anti-type 1 collagen (Southern Bio-
tech, Birmingham, AL, USA).
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Systems (Minneapolis, MN, USA). OA was purchased
from Sigma Aldrich. Tissue culture reagents, Dulbecco’s
modified Eagle medium (DMEM) and 100× antibiotic
antimycotic solution (penicillin streptomycin and
amphotericin B) were obtained from Gibco BRL (Grand
Island, NY, USA) and fetal bovine serum was purchased
from HyClone (Logan, UT, USA). Enhanced chemilumi-
nescence reagent and bovine serum albumin (BSA) pro-
tein assay reagent were obtained from Pierce (Rockford,
IL, USA). TriReagent was purchased from the Molecular
Research Center (Cincinnati, OH, USA). Primers were
purchased from Operon (Huntsville, AL, USA).
SMARTpool siRNA against PP2A C-subunit was pur-
chased from Dharmacon RNA Technologies (Lafayette,
CO, USA) and Hiperfect siRNA transfection reagent
from Qiagen (Germantown, MD, USA).
Cell culture
Human dermal fibroblast cultures were established from
biopsy specimens obtained from the dorsal forearms of
SSc patients with diffuse cutaneous disease and from
age, race and gender matched healthy donors, upon
informed consent and in compliance with the Institu-
tional Review Board. Dermal fibroblasts were cultured
from the biopsy specimens as described previously [15].
Normal and SSc skin fibroblasts were cultured in
DMEM supplemented with 10% FBS and 1% antibiotic
antimycotic solution. For experiments cells were pre-
treated with serum-free media for 24 h. Cells were trea-
ted with TGFb, 5 ng/ml.
Real-time PCR
Total RNA was isolated from dermal fibroblasts using
TriReagent (Molecular Research Center) according to
the manufacturer’s instructions. RNA (2 μg) was reverse
transcribed in a 20-μl reaction using random primers
and Transcriptor First Strand synthesis kit (Roche
Applied Sciences Indianapolis, IN. Quantitative (q)PCR
was carried out using IQ SYBR Green mixture (Bio-Rad,
Hercules, CA) on an iCycler PCR machine (Bio-Rad)
using 1 μlo fc D N Ai nt r i p l i c a t ew i t hb actin as the
internal control. The primers used are as follows. PP2A
C-subunit a isoform: forward, 5’-GCACTTGATCGCC-
TACAAGA-3’ and reverse, 5’-GAAATATCTTGCC-
CAAAGGTGT-3’. PP2A C-subunit b isoform: forward,
5’-TTCTTGTAGCATTAAAGGTGCGT-3’ and reverse,
5’-CATTCCCATACTTCGCAGACA-3’.
Immunoblotting
Whole cell protein extracts were prepared according to
the manufacturer’s recommendations (Pierce). Immuno-
blotting was performed as previously described [33].
RNA interference
SMARTpool siRNA directed against human PP2A cata-
lytic subunit was purchased from Dharmacon RNA
Technologies. Negative-control siRNA was purchased
from Qiagen (Chatsworth, CA, USA) and Hiperfect
transfection reagent (Qiagen) was used for transfection
of dermal fibroblasts according to the manufacturer’s
recommendations.
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